156264-80-1

Usage

Structure

A derivative of benzene with two bromine atoms at the 1 and 3 positions, and a tert-butyl group at the 5 position.

Organic synthesis

As a reagent for introducing bromine atoms into aromatic compounds.

Building block

For the synthesis of various pharmaceuticals and agrochemicals.

Physical state

Colorless to light yellow liquid at room temperature.

Odor

Distinct aromatic.

Flammability

Handle with care as it is flammable.

Skin and eye irritation

May cause skin and eye irritation upon contact.

Upstream product

• 156264-79-8 1-bromo-3-tert-butyl-5-nitrobenzene 

Downstream Products

• 1132941-44-6 (E)-N-(3-bromo-5-tert-butylphenylcarbamoyl)-3-methoxyacrylamide 
• 1234798-70-9 N-(3-tert-butyl-5-(4-methyl-1H-imidazol-1-yl)phenyl)-4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)benzamide 
• 1290090-22-0 C₁₄H₁₉N₃ 
• 22503-17-9 5-(tert-butyl)benzene-1,3-diamine 

Relevant academic research and scientific papers

UREA DERIVATIVES USEFUL AS KINASE INHIBITORS

There are provided compounds of formula I, wherein R1, R1A, R1C to R1E, Ra, Rb, X1, E and G have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C

Present application relates to the compounds of formula I useful to treat hepatitis C (HCV) infections. In the structure of the disclosed compounds is the uracil or thymine derivative linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two-atom linker (L) to a 5-6 membered monocycle (R6). Application further discloses polymorphs and pseudopolymorphs of two specific compounds: N-(6(3-t-butyl-5-(2>4-dioxo-3,4-dihydropyrimidin-1 (2H)- y!)2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide and (E)-N-(4(3-t- butyl-5-(2,4-dioxo-3)4-dihydropyrimidin-1 (2H)-yl)2-methoxy-styryl- phenyl)methanesulfonamide.

ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.